Adverum Biotechnologies doses first Wet AMD patient in phase-1 trial
Category: #health  By Pankaj Singh  Date: 2019-06-12
  • share
  • Twitter
  • Facebook
  • LinkedIn

Adverum Biotechnologies doses first Wet AMD patient in phase-1 trial

The California-based Adverum Biotechnologies Inc., which caters to the unmet medical requirements in rare and ocular diseases, has announced that it dosed its first wet AMD patient in the second cohort of its OPTIC phase 1 clinical trial for ADVM – 022 gene therapy. Reportedly, patients are receiving a single intravitreal injection of ADVM – 022 with a dosage of 2 x 10 ^11 vg/eye.

As per trusted sources, during the first phase of treatment, 6 patients were given ADVM – 022 at a dose of 6 x 10^11 vg/eye. In the second phase, the patients were given a dosage of 2 x 10^11 vg/eye owing to the strong preliminary anatomical response observed among patients in the first cohort. The primary endpoint of the trial is to test the safety and tolerability of the therapy at 24 weeks after giving the dosage to the patients. Each person undergoing the trial will be carefully monitored for a period of two years.

Arshad M. Khanani, M.A., M.D., trial investigator and director of clinical research department at Sierra Eye Associates, was reportedly quoted stating that ADVM – 022 has the ability to transform the prevailing treatment of neovascular AMD. A more consistent treatment can enhance long-term vision outcomes for patients in clinical practice in addition to alleviating the treatment burden, Khanani added.

For the record, ADVM – 022 uses a trademarked vector capsid (AAV.7m8) – which carries an aflibercept coding sequence – controlled by an expression cassette. It is then delivered as a sole intravitreal administration.

The existing therapy for treating wet AMD is anti-VEGF intravitreal injections. These injections work for a temporary period and need to be taken every 4-8 weeks to maintain vision gains.

Reportedly, eight foremost retinal care centers spread across the United States are anticipated to participate in the OPTIC phase 1 clinical trial of ADVM – 022.

 

Source: http://investors.adverum.com/news-releases/news-release-details/adverum-biotechnologies-doses-first-patient-second-cohort-optic



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Walgreens and Kroger to form a new group purchasing venture
Walgreens and Kroger to form a new group purchasing venture
By Pankaj Singh

Walgreens, a renowned U.S. based pharmacy-led health, beauty and well-being company, and Kroger, an American retail company, reportedly announced that they would be expanding their existing relationship to create a new...

GE Healthcare Life Sciences & ASLS unite to advance 3D biofabrication
GE Healthcare Life Sciences & ASLS unite to advance 3D biofabrication
By Pankaj Singh

 

  • The alliance is aimed at personalizing regenerative tissue manufacturing processes
  • Vascularized printed cells are set to pave the way for more complex biolog...

Hummingbird Bio secures $19M to expand antibody therapeutics portfolio
Hummingbird Bio secures $19M to expand antibody therapeutics portfolio
By Pankaj Singh

Hummingbird Bioscience, an advanced biotherapeutics company, recently announced it has raised USD 19 million in a Series B funding round. Apparently, the financing round was co-led by GNTech Venture Capital and Mirae A...